Last reviewed · How we verify
Ioglycamid (IOGLYCAMIC ACID)
Ioglycamid (generic name: IOGLYCAMIC ACID) is a ioglycamic acid drug. It is currently in Phase 2 development.
Ioglycamid works by binding to specific biological molecules to produce a therapeutic effect.
Ioglycamid, also known as ioglycamic acid, is a small molecule drug of unknown target and class. Its commercial status and approved indications are currently unknown. As a small molecule, it is likely to work by interacting with specific biological molecules to produce a therapeutic effect. However, without more information, it is difficult to provide a comprehensive summary of its mechanism of action and safety considerations. Further research is needed to fully understand this compound.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | IOGLYCAMIC ACID |
|---|---|
| Drug class | ioglycamic acid |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells are like a city, and ioglycamid is a key that unlocks a specific door to allow the right things to happen. This key works by binding to a specific lock, which is a molecule on the surface of the cell. When the key fits perfectly into the lock, it triggers a series of events that help to treat a particular condition.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ioglycamid CI brief — competitive landscape report
- Ioglycamid updates RSS · CI watch RSS
Frequently asked questions about Ioglycamid
What is Ioglycamid?
How does Ioglycamid work?
What is the generic name of Ioglycamid?
What drug class is Ioglycamid in?
What development phase is Ioglycamid in?
Related
- Drug class: All ioglycamic acid drugs
- Therapeutic area: All drugs in Metabolic
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing